Inclusion Criteria:  Presenting dry eye symptoms for at least 6 months. OSDI (Ocular Surface Disease Index) ≥ 18  At least one eye eligible with:  sum of peripheral corneal and conjunctival staining ≥ 4 and ≤ 9 (Oxford 0-15 grading scheme) AND sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 15s Meibomian Gland Dysfunction on at least one eye (same eye eligible) with a score of 1 or higher for meibum quality score (from 0: clear to 3: toothpaste/obstruction) and evidence of partial or whole missing Meibomian Glands. Ability and willingness to apply eyelid hygiene during the whole study, including wash-out period. Having given freely and expressly his/her informed consent. Able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation. In France: subject being affiliated to a health social security system. Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.  Exclusion Criteria:  Pregnant or nursing woman or planning a pregnancy during the study. Subject deprived of freedom by administrative or legal decision. Subject in a social or health institution Subject who is under guardianship or who is not able to express his/her consent. Use of contact lenses in either eye during the study. Far best-corrected visual acuity ≤ 1/10.  Subject with severe ocular dryness with one of these conditions:  Eyelid or blinking malfunction Corneal disorders not related to dry eye syndrome Ocular metaplasia Filamentous keratitis Corneal neovascularization History of ocular traumatism, ocular infection or ocular inflammation within the last 3 months. History of ocular allergy or ocular herpes within the last 12 months. Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months. Any troubles of the ocular surface not related to dry eye syndrome. Use of the following ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus during the month preceding the inclusion. IOP > 21 mmHg Uncontrolled systemic disease Alcohol abuse Psychiatric disorders Cognitive impairment that could affect evaluation of preferences or inability to understand written patient information Participation in other clinical studies in the last month Hypersensitivity to one or more components of the study product Dry eye due to systemic disease, concomitant medication, malign conditions or idiopathic causes Punctual plugs during the past 3 months Use of lipid-containing eye drops during the past 3 months Use of other therapeutic ophthalmics during the past 3 months Earlier participation at this clinical trial or the patient being an investigator or a member of the personnel involved at this clinical trial